Search results for "Advanced disease"

showing 10 items of 15 documents

Management of chronic otitis by middle ear obliteration with blind sac closure of the external auditory canal.

2008

Objective: Description of a technique of middle ear obliteration (MEO) with blind sac closure of the external auditory canal with discussion of the indications for its use in cases of recalcitrant chronic otitis and in far advanced disease. Patients: All patients underwent otologic examination and audiologic and radiologic assessments in a quaternary center. Results: Fifty-three cases of MEO were analyzed. For 9 patients, primary surgery was performed. One case of residual disease was identified. The minimum follow-up was 2 years. Conclusion: The decision to perform a MEO is one that is made only rarely. However, this is a technique that should be part of every otologist`s armamentarium. Wh…

AdultMalemedicine.medical_specialtyAdolescentMiddle ear obliterationChronic otitisEar MiddleChronic otitisMeningoceleMastoidAuditory canalQuality of lifeotorhinolaryngologic diseasesmedicineAdvanced diseaseHumansChildCholesteatomaLabyrinthitisMeningoencephalic herniationAgedAged 80 and overbusiness.industryMiddle AgedMagnetic Resonance ImagingSensory SystemsSurgerymedicine.anatomical_structureOtorhinolaryngologyChronic DiseaseQuality of LifeMiddle earFemaleNeurology (clinical)Otologic Surgical ProceduresTomography X-Ray ComputedbusinessEar CanalFollow-Up Studies
researchProduct

Numerical, dimensional or mixed progression disease to imatinib as prognostic factor in patients with metastatic GIST.

2017

11040 Background: The majority of GIST patients with advanced disease initially achieves disease control from imatinib treatment. Approximately 10% of patients progresses within 6 months of starting therapy (primary resistance) and also 50-60% of the responding patients develops progression disease within two years (secondary resistance). Progression disease (PD) can be numerical, dimensional or mixed. The known prognostic factors of risk stratification in local disease are tumor size, mitotic activity and anatomic site. In this retrospective analysis we explore several clinical factors affecting survival in metastatic setting. Methods: The population included in this large database of 128…

OncologyCancer Researchmedicine.medical_specialtyPrognostic factorGiSTbusiness.industryImatinibDiseaseDisease controlMetastatic gistOncologyInternal medicineAdvanced diseaseMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy

2019

Abstract Background Lung cancer is the leading cause of cancer-related mortality worldwide. At diagnosis, 70% of patients present advanced disease being chemotherapy the standard of care. Although, specific tumour biomarkers that allow a better treatment selection and monitoring is absent at the moment. Enumeration and characterization of circulating tumor cells (CTCs) have the potential to perform as a prognostic biomarker for a precision medicine approach to lung cancer care. The present study was conducted to validate the characterization CTCs from patients with advanced Non-small cell lung cancer (NSCLC) as a valuable tool for anticipating the disease evolution and the therapy response.…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentHematologyPrecision medicinemedicine.diseaseCirculating tumor cellOncologyInternal medicinemedicineAdvanced diseasePrognostic biomarkerChristian ministryNon small cellLung cancerbusinessAnnals of Oncology
researchProduct

Multidisciplinary intervention in the management of breathlessness in people with non-malignant chronic diseases in advanced situation

2018

Resumen El presente trabajo muestra una revisión crítica de un artículo en que se presentan los resultados de un ensayo clínico realizado en un hospital de Reino Unido para estudiar los resultados de una intervención con enfoque paliativo utilizada en el manejo de la disnea en pacientes con enfermedades crónicas en fases avanzadas. Tras el resumen del artículo, destacando los principales resultados obtenidos, se presenta la revisión crítica del artículo, en la que se ha intentado analizar tanto el diseño como la metodología utilizada en el ensayo clínico, como las implicaciones para la práctica de enfermería y especialmente en el ámbito de los cuidados paliativos. Abstract This work shows a…

Scientific evidenceRRT1-120Multidisciplinary interventionNursingEnfermedad avanzadaIntervención multidisciplinarCuidados paliativosAdvanced diseaseDyspneaInfermeriaTractament pal·liatiuPalliative careEvidencia científicaMedicineEnfermeríaDisneaIndex de Enfermería
researchProduct

Strong Expression of Chemokine Receptor CXCR4 by Renal Cell Carcinoma Correlates with Advanced Disease

2008

Diverse chemokines and their receptors have been associated with tumor growth, tumor dissemination, and local immune escape. In different tumor entities, the level of chemokine receptorCXCR4 expression has been linked with tumor progression and decreased survival. The aim of this study was to evaluate the influence ofCXCR4 expression on the progression of human renal cell carcinoma.CXCR4 expression of renal cell carcinoma was assessed by immunohistochemistry in 113 patients. Intensity ofCXCR4 expression was correlated with both tumor and patient characteristics. Human renal cell carcinoma revealed variable intensities ofCXCR4 expression. StrongCXCR4 expression of renal cell carcinoma was si…

Pathologymedicine.medical_specialtyChemokineArticle Subjectbiologybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCXCR4lcsh:RC254-282Chemokine receptorOncologyTumor progressionRenal cell carcinomaAdvanced diseasebiology.proteinMedicineImmunohistochemistrybusinessReceptorResearch ArticleJournal of Oncology
researchProduct

Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients

2012

Since the introduction of prostate-specific antigen (PSA) testing, new prostate cancer (PCa) patients are diagnosed earlier and most have localized and locally advanced disease. Current diagnosis methods lack specificity and sensitivity, leading to overdiagnosis and overtreatment of patients with low-risk organ-confined localized disease. Therefore, new non-invasive molecular tools are needed to discriminate between localized and locally advanced disease.Plasma telomerase reverse transcriptase (hTERT) mRNA levels were determined by qRT-PCR in 49 patients with localized and locally advanced PCa. Diagnostic accuracy and efficacy as a prognostic factor of biochemical recurrence of plasma hTERT…

MaleOncologyBiochemical recurrencemedicine.medical_specialtyPathologyTelomeraseClinical BiochemistryProstate cancerAntigenRecurrenceInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansTelomerase reverse transcriptaseRNA MessengerOverdiagnosisTelomeraseAgedNeoplasm StagingPharmacologybusiness.industryProstatic NeoplasmsMiddle Agedmedicine.diseaseROC CurveArea Under CurveLocalized diseaseLocally advanced diseasebusinessExpert Opinion on Biological Therapy
researchProduct

Autonomic dysfunction in a group of lower extremities arterial disease outpatients.

2021

Background: The understanding of the specific role of sympathetic neural control and dysregulation in lower extremities arterial disease (LEAD) is still very limited. Aim of our study was to investigate the autonomic profile in LEAD patients and to evaluate if the eventual autonomic alterations were more severe in patients with advanced disease. Methods: We enrolled all consecutive outpatients with LEAD referred to our Departments between July 2012 and September 2014. They were compared to a group of matched outpatients without LEAD. All patients underwent Holter ECG monitoring. Time-domain analysis of heart rate variability (HRV) was evaluated. Results: Compared to controls, patients with …

medicine.medical_specialtyArterial diseasebusiness.industrySevere diseaseDiseaseAutonomic Nervous SystemLower ExtremityHeart RateInternal medicineOutpatientsAdvanced diseaseCardiologyElectrocardiography AmbulatoryMedicineHeart rate variabilityHumansStage (cooking)Cardiology and Cardiovascular MedicineLead (electronics)businessHumanHolter ecgMinerva cardiology and angiology
researchProduct

Why Do We Have to Use Chemotherapy?

2018

The use of chemotherapy (CT) in localized rectal cancer (LARC) has two aims: first, to improve the local effect of radiotherapy by giving concomitant chemoradiation and second, to decrease systemic relapses by early treatment for occult micrometastatic disease or to shrink bulky local tumours. Neoadjuvant treatment is reserved for locally advanced disease, as defined by pelvic magnetic resonance imaging, a very useful and accurate tool to identify high-risk features for local or systemic relapse [1]. We are going to address why we have to use CT in LARC.

medicine.medical_specialtyChemotherapymedicine.diagnostic_testbusiness.industryColorectal cancermedicine.medical_treatmentMagnetic resonance imagingmedicine.diseaseOccultRadiation therapyNeoadjuvant treatmentLocally advanced diseaseConcomitantMedicineRadiologybusiness
researchProduct

Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.

2017

The European Association for the Study of the Liver Hepatocellular Carcinoma (HCC) international meeting held in Geneva in February 2017 focused on the state of the art of HCC management, from diagnosis to treatment and the potential development of clinical research in this field. This report reviews some of the most interesting topics discussed at the meeting such as the role of hepatitis C viral infection treatment with direct-acting antivirals in enhancing HCC risk, current prognostic systems, early diagnosis techniques, curative therapies for early HCC and the systemic treatments for advanced disease with a look into future perspectives.

OncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsHepacivirusGastroenterologyAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdvanced diseaseHumansNeoplasm StagingHepatitis c viralgeographyClinical Trials as TopicSummitgeography.geographical_feature_categorybusiness.industryLiver NeoplasmsGeneral MedicineCongresses as TopicHepatitis C Chronicmedicine.diseasePrognosisCombined Modality Therapydigestive system diseasesClinical researchOncologyLiver030220 oncology & carcinogenesisHepatocellular carcinomaEarly hccCatheter AblationDisease Progression030211 gastroenterology & hepatologybusinessSwitzerlandFuture oncology (London, England)
researchProduct

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

2015

BACKGROUND: Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease.METHODS: Multivariable analyses of the final dataset from the ABC-02 study were carried out. All variables were simultaneously included in a Cox proportional hazards model, and backward elimination was used to produce the final model (using a significance level of 10%), in which the selected variables were associated independently with outcome. This score was validated externally by receiver operating curve (ROC) analysis using…

Oncologymedicine.medical_specialtyDisease-Free SurvivalCholangiocarcinoma03 medical and health sciencesAdvanced diseaseCisplatin and gemcitabine0302 clinical medicineInternal medicinemedicineJournal ArticleHumansProgression-free survivalProportional Hazards ModelsPerformance statusReceiver operating characteristicManchester Cancer Research Centrebusiness.industryProportional hazards modelResearch Support Non-U.S. Gov'tResearchInstitutes_Networks_Beacons/mcrcHazard ratioArea under the curveCancerHematologymedicine.diseasePrognosisConfidence intervalSurgeryTreatment OutcomeOncologyBile Duct NeoplasmsROC Curve030220 oncology & carcinogenesisABC-02Multivariate AnalysisBiliary tract cancer030211 gastroenterology & hepatologybusinessPerformance statusPrognostic modelMeta-Analysis
researchProduct